Navigation Links
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Date:2/6/2008

rade 3/4 elevated total bilirubin reported among atazanavir recipients in each of the groups, respectively. There were no opportunistic infections reported in the vicriviroc groups compared to two in the control group, and no systemic malignancies reported in any of the groups in the 48- week study.

These results supported the selection of the 30 mg once-daily vicriviroc dose for use in ongoing Phase III clinical studies.

About Vicriviroc Ongoing Phase III Studies

Building on the results of the VICTOR-E1 study, Schering-Plough is currently enrolling patients in two large global Phase III clinical studies with vicriviroc administered once-daily as a single 30 mg tablet in adult treatment-experienced HIV patients with R5-type virus only.

The two ongoing Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV-Infected Treatment-Experienced Subjects), evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The optimized background therapy must include at least two drugs to which the patient's HIV is susceptible. Patients coinfected with hepatitis B or C may be included in these studies and there are no exclusions of commonly prescribed drugs or need for dose adjustments based on the known vicriviroc drug-drug interaction profile. The two studies are currently enrolling approximately 375 patients each at more than 160 sites in North America, Latin America, Europe, Australia and South Africa.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own bi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
4. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
5. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... The LIV Fertility Center in Puerto Vallarta ... the right age to pursue egg freezing. Statistics show that 20 percent of women ... a 150 percent increase since the 1970s. , Sadly, for women who have delayed ...
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... 2007 to 2013 while heroin-related deaths more than tripled in the same period—leading a ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, 2015 , ... ... Reasons You Have Acne ,” listed five triggers that most people would not ... cloths, hair care products, and toothpaste. The primary causes of acne are ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... Annual Alzheimer's Association of Colorado's Education Symposium on November 9, 2015 at the ... honored to host a conversation with Kim and Ashley Campbell, the wife and ...
(Date:6/30/2015)... ... June 30, 2015 , ... Dr. Sammy Masri of Masri Sports ... He specializes in the diagnosis and treatment of non-surgical sports and other musculoskeletal injuries ... participate in recreational athletics and use exercise to stay healthy and active. Dr. Masri ...
Breaking Medicine News(10 mins):Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5
... and EMERYVILLE, Calif., Sept. 30 Bayer HealthCare ... ) today announced results from a randomized, placebo-controlled ... The study, which evaluated Nexavar® (sorafenib) tablets in ... with locally advanced or metastatic HER-2 negative breast ...
... who self-rated themselves as being sexually satisfied had a ... well-being" and "vitality," compared with sexually dissatisfied women in ... twice a month. The study, published today in ... a positive association between age and well-being, but a ...
... Less than half of men and women in Ontario ... treat their potentially debilitating condition, according to a new women,s ... Institute for Clinical Evaluative Sciences (ICES). What,s more, many hospitalized ... care within 30 days of being discharged, and many head ...
... long, healthy life by nearly 80%, study finds , , ... you by old age, it could make your life miserable in ... , According to a new study, women who are obese ... multiple health problems by the time they reach age 70. , ...
... slippers and high heels contributes to aching feet later on, ... women who make poor shoe choices risk foot pain later ... data from 1,900 women and 1,472 men enrolled in the ... asked about pain, aching, or stiffness in either or both ...
... shows , TUESDAY, Sept. 29 (HealthDay News) -- ... fact, U.S. researchers say recessions may actually be good ... death rates during the Great Depression, the worst economic ... crash of 1929 through the early 1930s, economic activity ...
Cached Medicine News:Health News:Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer 2Health News:Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer 3Health News:Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer 4Health News:Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer 5Health News:Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer 6Health News:Sexually satisfied women have better general well-being and more vitality 2Health News:Sexually satisfied women have better general well-being and more vitality 3Health News:Less than 50 percent of men and women with depression see a doctor for treatment 2Health News:Obese Middle-Aged Women Face Unhealthy Future 2Health News:Those Stilettos Can Hurt You Years From Now 2Health News:Could the Recession Be Good for Your Health? 2Health News:Could the Recession Be Good for Your Health? 3Health News:Could the Recession Be Good for Your Health? 4
(Date:6/30/2015)... , June 30, 2015  Ardelyx, Inc. (NASDAQ: ... gastrointestinal and metabolic diseases, today announced that the Company ... 2015, from 8:00 a.m.- 1:00 pm EDT in ... The Ardelyx senior management team will present an overview ... tenapanor, which has completed Phase 2b clinical trials for ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... , June 30, 2015  Egalet Corporation ... integrated specialty pharmaceutical company focused on developing, ... announced top-line results from a Category 3 ... an abuse-deterrent, extended-release, oral oxycodone product candidate ... of pain severe enough to require daily, ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... NEW CENTERS AND TO ... INCREASE AWARENESS AMONG CARDIOLOGISTS, PLEASANTON, Calif., April 21 ... mechanical,circulatory support therapies to save, support and restore failing hearts,said ... (PreMarket,Approval) application, allowing the use of its HeartMate II LVAS ...
... April 21 A new study funded by,Health ... correlation,between dietary consumption of the omega-3 DHA* and ... Universite Laval,researchers and published in the Journal of ... pregnancy boosts an infant,s sensory,cognitive, and motor development., ...
Cached Medicine Technology:Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 2Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 3Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 4Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 5Pregnant Women Need Omega-3 to Boost Infant Development 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: